NIH Phase 1 Exploratory/Developmental Cooperative Agreement (UG3)
Funds Phase 1 Exploratory/Developmental Cooperative Agreement, NIH's UG3 mechanism.
The National Institutes of Health describes the Phase 1 Exploratory/Developmental Cooperative Agreement (UG3) this way: As part of a bi-phasic approach to funding exploratory and/or developmental research, the UG3 provides support for the first phase of the award. This activity code is used in lieu of the UH2 activity code when larger budgets and/or project periods are required to establish feasib…
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds a biologic for a nervous system disorder from lead optimisation to phase I, with NIH-paid manufacturing and tox work — and the applicant keeps the IP.
Funds stroke trials and biomarker studies run inside NIH's national StrokeNet — with its coordinating centres doing recruitment and data.
Funds the planning of a clinical trial in oral, dental or craniofacial health, and then running it, as one phased award.
Funds the implementation of a clinical trial in arthritis, musculoskeletal or skin disease as a phased cooperative agreement with the institute.
Funds up to two years planning a behavioural or social intervention trial in oral health, then up to five running it if the milestones are met.
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Funds collaborative projects that build, test and spread new tools or methods across NIH's national network of clinical and translational research hubs.
Funds multisite clinical trials and studies for infants, children, pregnant or lactating women, or people with disabilities, through NICHD's own network.
Funds the translational and first clinical-feasibility steps for a device treating a nervous-system or neuromuscular disorder.
Funds discovering and developing a medication or device to prevent or treat substance use disorders and overdose, in two phases.
Funds a multi-center clinical trial or ancillary study run inside an already-funded NIH Clinical Trial Research Network, in two milestone-driven phases.
Funds the Clinical Coordinating Center that runs a multi-site heart, lung or blood trial, paired with a data-center twin.
Funds community-based research testing policies and cross-sector partnerships that address the risk factors driving unequal oral disease.
Funds an investigator-led, multi-site clinical trial in two phases — up to two years to start up, five more to run it.
Funds taking a brain recording or stimulation device from prototype through safety testing and an FDA exemption into a first small clinical study.
Funds optimizing an existing non-addictive pain drug or biologic candidate through IND filing and into a first human trial.
Funds a company and an academic team to build and test an imaging-centred multimodal AI decision tool, developed as software that is a medical device.
Funds the move of an imaging-centred multimodal AI tool from a trained and tested prototype towards real clinical use, as regulated device software.